We are live on ! Find out more
HALO icon

Halozyme

132 hedge funds and large institutions have $882M invested in Halozyme in 2014 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

19% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 36

9% more funds holding

Funds holding: 121132 (+11)

9% more capital invested

Capital invested by funds: $810M → $882M (+$72.4M)

34% less call options, than puts

Call options by funds: $8.6M | Put options by funds: $13M

Holders
132
Holders Change
+11
Holders Change %
+9.09%
% of All Funds
3.52%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
27
Increased
43
Reduced
36
Closed
13
Calls
$8.6M
Puts
$13M
Net Calls
-$4.42M
Net Calls Change
-$7.17M

HALO Hedge Fund Activity: Q4 2014 in Review

132 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2014, worth a combined $882M — up 8.9% from $810M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new HALO positions and 13 closed out — a net gain of 14 holders — while 43 added to existing stakes and 36 trimmed.

The largest buyer was Lombard Odier Asset Management (USA), adding an estimated $10.7M. The largest seller was QVT Financial, cutting an estimated $18.2M.

  • 132 institutional investors held Halozyme (HALO) as of Q4 2014, up from 121 in Q3 2014.
  • Funds reported $882M of Halozyme stock for Q4 2014, up 8.9% quarter-over-quarter.
  • 27 funds opened new Halozyme positions in Q4 2014 and 13 closed out, a net change of +14 holders.
  • The largest Halozyme buyer in Q4 2014 was Lombard Odier Asset Management (USA), an estimated $10.7M added.
  • The largest Halozyme seller in Q4 2014 was QVT Financial, an estimated $18.2M sold.

Based on aggregated 13F filings for Q4 2014.